Precision BioSciences Inc (NASDAQ:DTIL) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 702,200 shares, a growth of 31.0% from the August 30th total of 535,900 shares. Currently, 2.2% of the company’s shares are sold short. Based on an average daily trading volume, of 147,200 shares, the days-to-cover ratio is presently 4.8 days.
Shares of NASDAQ:DTIL traded down $0.19 on Friday, reaching $7.22. 178,055 shares of the company traded hands, compared to its average volume of 209,536. The business has a 50-day simple moving average of $8.57. Precision BioSciences has a 52 week low of $7.11 and a 52 week high of $19.00.
Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.08. The company had revenue of $5.39 million for the quarter, compared to the consensus estimate of $8.18 million. As a group, research analysts expect that Precision BioSciences will post -1.71 EPS for the current fiscal year.
Several institutional investors have recently bought and sold shares of DTIL. Strs Ohio purchased a new stake in shares of Precision BioSciences during the second quarter worth about $31,000. Ladenburg Thalmann Financial Services Inc. purchased a new stake in shares of Precision BioSciences during the second quarter worth about $33,000. Royal Bank of Canada purchased a new stake in shares of Precision BioSciences during the second quarter worth about $38,000. MUFG Americas Holdings Corp purchased a new stake in shares of Precision BioSciences during the second quarter worth about $51,000. Finally, Edge Wealth Management LLC purchased a new stake in shares of Precision BioSciences during the second quarter worth about $53,000. Institutional investors own 43.66% of the company’s stock.
A number of research analysts have recently issued reports on DTIL shares. HC Wainwright started coverage on Precision BioSciences in a research note on Tuesday, July 16th. They set a “buy” rating and a $21.00 price objective on the stock. BTIG Research started coverage on Precision BioSciences in a research note on Friday, August 9th. They set a “buy” rating and a $22.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, Precision BioSciences currently has an average rating of “Buy” and a consensus target price of $22.80.
Precision BioSciences Company Profile
Precision BioSciences, Inc operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities.
Featured Story: Day Trading
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.